Biosimilars are increasing the number of safe, effective treatments for cancer. How can policies ensure that they’re accessible for oncologists to personalize cancer care?
Biosimilars are increasing the number of safe, effective treatments for cancer. How can policies ensure that they’re accessible for oncologists to personalize cancer care?